Results 31 to 40 of about 17,845 (225)

Pro-Inflammatory Interactions of Dolutegravir with Human Neutrophils in an In Vitro Study

Molecules, 2022
There is increasing awareness of an association between the uptake of the HIV integrase inhibitor, dolutegravir, in first-line antiretroviral regimens with unusual weight gain and development of the metabolic syndrome, particularly in African women ...
Annette J. Theron, Ronald Anderson, Morris Madzime, Theresa M. Rossouw, Helen C. Steel, Pieter W. A. Meyer, Moloko C. Cholo, Luyanda L. I. Kwofie, Charles Feldman, Gregory R. Tintinger   +9 more
doaj   +1 more source

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

BMC Infectious Diseases, 2019
Background Direct comparisons between lamivudine plus bPIs and lamivudine plus dolutegravir as maintenance strategies in virologically-suppressed HIV positive patients are lacking.
Alberto Borghetti, Francesca Lombardi, Roberta Gagliardini, Gianmaria Baldin, Arturo Ciccullo, Davide Moschese, Arianna Emiliozzi, Simone Belmonti, Silvia Lamonica, Francesca Montagnani, Elena Visconti, Andrea De Luca, Simona Di Giambenedetto   +12 more
doaj   +1 more source

Breaking the unbreakable: A paediatric case of dolutegravir resistance from KwaZulu-Natal

Southern African Journal of HIV Medicine, 2023
We report a case of dolutegravir resistance in KwaZulu-Natal in a 13-year-old male two years after starting dolutegravir. Resistance most likely developed due to poor adherence as a result of psychosocial issues.
Sibongiseni Malinga, Aabida Khan, Moherndran Archary   +2 more
doaj   +1 more source

Dolutegravir potentiates platelet activation by a calcium-dependent, ionophore-like mechanism

Journal of Immunotoxicology, 2022
Dolutegravir is a highly potent HIV integrase strand transfer inhibitor that is recommended for first-line anti-retroviral treatment in all major treatment guidelines.
Morris Madzime, Annette J. Theron, Ronald Anderson, Gregory R. Tintinger, Helen C. Steel, Pieter W. A. Meyer, Jan G. Nel, Charles Feldman, Theresa M. Rossouw   +8 more
doaj   +1 more source

Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland

SAGE Open Medicine, 2016
Objective: Dolutegravir, an HIV integrase inhibitor, is a relatively new treatment option. To assess the tolerability, side effects, and time to viral decline to non-detectable in patients newly started on dolutegravir. Methods: Retrospective health care
Sarmad Waqas, Mairead O’Connor, Ciara Levey, Paddy Mallon, Gerard Sheehan, Anjali Patel, Gordana Avramovic, John S Lambert   +7 more
doaj   +1 more source

Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens

South African Journal of Psychiatry, 2023
Background: Neurocognitive disorders due to human immunodeficiency virus (HIV) remain highly prevalent, specifically mild forms despite effective antiretroviral therapy (ART).
Janine Rodrigues, Karishma Lowton
doaj   +1 more source

Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity : An Observational Study.

, 2021
BACKGROUND The transition to dolutegravir-containing antiretroviral therapy (ART) in low- and middle-income countries (LMICs) was complicated by an initial safety signal in May 2018 suggesting that exposure to dolutegravir at conception was possibly ...
Bernard, Caitlin, Panczak, Radoslaw, Musick, Beverly S, Ly, Penh Sun, Maina, Mercy W, Wools-Kaloustian, Kara K, Cortés, Claudia P, Romo, Matthew L., Wagner Cardoso, Sandra, Cardoso, Sandra Wagner, Patel, Rena C, Patel, Rena C., Penner, Jeremy, Cortés, Claudia P., Kunzekwenyika, Cordelia, Kelvin, Elizabeth A, Kelvin, Elizabeth A., Brazier, Ellen, Humphrey, John M, Romo, Matthew L, Castelnuovo, Barbara, Humphrey, John M., Nash, Denis, Edwards, Jessie K, Maina, Mercy W., Wools-Kaloustian, Kara K., International epidemiology Databases to Evaluate AIDS (IeDEA), Wyka, Katarzyna, Edwards, Jessie K., Musick, Beverly S.   +29 more
core   +1 more source

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial [version 1; peer review: 2 approved, 1 approved with reservations]

Wellcome Open Research, 2021
Background: Dolutegravir has superior efficacy and tolerability than lopinavir-ritonavir in second-line antiretroviral therapy after failure of a first-line non-nucleoside reverse transcriptase inhibitors-based regimen, when dolutegravir is accompanied ...
Zimasa Gcwabe, Kaneez Sayed, Charlotte Schutz, Olina Ngwenya, Eric Goemaere, Rene Goliath, Amanda Jackson, Rulan Griesel, Andrew Hill, Graeme Meintjes, Tali Cassidy, Claire Keene, Ying Zhao, Gary Maartens   +13 more
doaj   +1 more source

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.

New England Journal of Medicine, 2019
BACKGROUND Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF).
W. Venter, Michelle A. Moorhouse, Simiso M Sokhela, L. Fairlie, Nkuli Mashabane, Masebole Masenya, Celicia M. Serenata, Godspower Akpomiemie, A. Qavi, N. Chandiwana, Shane Norris, M. Chersich, P. Clayden, E. Abrams, Natasha Arulappan, A. Vos, K. McCann, Bryony Simmons, A. Hill   +18 more
semanticscholar   +1 more source

Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation

Viruses, 2020
With the current widespread use of dolutegravir in low-income countries, the understanding of the impact of nucleoside reverse transcriptase inhibitor (NRTI-) associated mutations on the efficacy of dolutegravir-containing antiretroviral therapy (ART) is
Dominique L. Braun, Thomas Scheier, Ulrich Ledermann, Markus Flepp, Karin J. Metzner, Jürg Böni, Huldrych F. Günthard   +6 more
doaj   +1 more source